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Available online 16 February 2012Previous evidence indicates that a balance between inhibitory gabaergic and excitatory
angiotensinergic factors in the PVN is important for cardiovascular control. We investigated
the cardiovascular response evoked from activation or blockade of GABAA receptors in the
paraventricular nucleus (PVN), in transgenic rats with low brain angiotensinogen
[TGR(ASrAOGEN)]. Brain Ang II and Ang-(1–7) levels were also determined. In functional
experiments, TGR(ASrAOGEN) and Sprague–Dawley rats (SD, control) were anesthetized
with urethane and blood pressure (BP), heart rate (HR) and renal sympathetic nerve
activity (RSNA) were recorded. Brain Ang II and Ang-(1–7) levels were largely reduced
in TGR(ASrAOGEN) compared with SD rats. Inhibition of PVN neurons with the GABAA
agonist, muscimol (1 nmol/100 nL), resulted in an attenuated fall in all cardiovascular
variables in TGR(ASrAOGEN) compared with SD rats. This difference was particularly
pronounced in HR (TGR Mus −23±6 bpm vs. −77±9 bpm SD Mus; P<0.05) and RSNA
(TGR −3±10% vs.−29±8% SD; P<0.05). Furthermore, the sympathetic response evoked
by blockade of GABAA receptors in the PVN of TGR(ASrAOGEN) was also largely
suppressed. The present data indicate that the sympathetic outflow mediated by PVN
neurons under basal conditions is suppressed in TGR(ASrAOGEN) rats corroborating
the functional significance of brain angiotensin production in the central regulation of
sympathetic output to the cardiovascular system.
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Brain renin-angiotensin system (RAS) is implicated in
cardiovascular system control by interfering with the activity
of sympathetic premotor neurons (Bader et al., 2001;
Veerasingham and Raizada, 2003). Evidence indicates that
RAS peptides might influence baseline sympathetic output by
exciting premotor neurons of hypothalamic paraventricular
nucleus (PVN) (Silva et al., 2005; Zucker et al., 2004). A high
density of angiotensin II (Ang II) receptors is found in the PVN
neurons (McKinley et al., 2003) and their stimulation or blockade
may influence the sympathetic activity in physiological (Silva et
al., 2005) or altered conditions (ChenandToney, 2001; daSilva et
al., 2011; Zhu et al., 2004).
The central GABA system plays an important role in
cardiovascular control. PVN is a key site where GABA elicits an
inhibitory effect on cardiovascular functions and sympathetic
activity (Haywood et al., 2001; Martin et al., 1991). Blockade of
gabaergic input in the PVN profoundly increases sympathetic
outflow (Tagawa and Dampney, 1999), whereas activation of
GABAA receptors in the PVN reduces sympathetic activity and
blood pressure (Allen, 2002; Silva et al., 2005). It has been postu-
lated that the overall increase in basal sympathetic tone in
cardiovascular diseases such as in heart failure is caused, at
least in part, by an unbalance between the inhibitory gabaergic
and excitatory angiotensinergic factors within the PVN (Li and
Patel, 2003; Zucker et al., 2004).
To study the functional relevance of the brain RAS we
developed a transgenic model with low levels of brain angio-
tensinogen (AOGEN), named TGR(ASrAOGEN). This rat model
expresses antisense RNA against AOGEN to suppress its
production by the astrocytes (Schinke et al., 1999), the major
source of brain AOGEN (Milsted et al., 1990). Indirect evidence
suggests that TGR(ASrAOGEN) has a diminished sympathetic
tone (Baltatu et al., 2004b;Wang et al., 2004).Wehavepreviously
reported that injections of Ang II into the rostral ventrolateral
medulla of TGR(ASrAOGEN) evoke a larger pressor response
when compared to that observed in control SD rats (Baltatu
et al., 2001). This finding leads us to conclude that a permanent
reduction of AOGEN in the brain results in an increased sensi-
tivity ofAng II receptors. In this studyweutilized this transgenic
model to test the hypothesis that the reduction in brain Ang II
may affect the cardiovascular effects mediated by activation
or blockade of GABAA receptors in the PVN. Therefore we
(i) determined the levels of Ang peptides in the brain of
TGR(ASrAOGEN), (ii) evaluated the renal sympathetic tone in
TGR(ASrAOGEN), (iii) tested the cardiovascular reactivity to
activation or blockade of GABAA receptors in the PVN of
TGR(ASrAOGEN).2. Results
Radioimmunoassay measurements revealed that transgene
expression leads to a marked reduction in Ang II and
Ang-(1–7) formation in the brain of TGR(ASrAOGEN) when
compared with control rats. On the other hand, plasma levels
of Ang I, Ang II and Ang-(1–7) and plasma renin activity were
not different between TGR(ASrAOGEN) and SD rats (Fig. 1).Table 1 shows thebaselineMAPandHR just before injections
of muscimol or bicuculline into the PVN of TGR(ASrAOGEN) or
SD rats. No significant difference among groups was observed
for MAP and HR. Fig. 2 shows grouped data illustrating the
cardiovascular effects evoked by microinjections of muscimol
(1 nmol/100 nL) into the PVN of TGR(ASrAOGEN) and SD rats.
When compared to the effects evoked by muscimol into the
PVN of SD rats, microinjections of muscimol into PVN of
TGR(ASrAOGEN) resulted in an attenuated fall in MAP (TGR mus:
−17±5mm Hg vs SD mus: −32±3mm Hg) and HR (TGR mus:
−23±6 bpm vs SD mus: −77±9 bpm). Microinjections of musci-
mol into the PVN of TGR(ASrAOGEN) did not significantly alter
baseline RSNA (−3±10%), in contrast to the large decrease in
RSNA produced by muscimol injections into PVN of SD rats
(SD mus:−29±8%). This is more clearly illustrated in Fig. 3,
which shows examples of filtered renal neurogramsand the av-
erage RSNA, calculated as spikes/s. As described for MAP and
HR, no significant difference was observed in the basal levels
of RSNA between TGR(ASrAOGEN) and SD rats (Figs. 3A–C).
Muscimolmicroinjections into PVN, caused a smaller reduction
in baseline sympathetic activity in TGR(ASrAOGEN) when com-
pared to SD rats (Fig. 3D). In an additional series of experiments
we observed that intravenous injection of hexamethonium
also produced an attenuated fall in MAP, HR and RSNA in
TGR(ASrAOGEN) when compared to SD rats (Fig. 4).
Finally, we compared the cardiovascular response
produced by blockade of GABAA receptors into the PVN of
SD and TGR(ASrAOGEN). We found that the increases in HR
and RSNA evoked by bicuculline injections into the PVN of
TGR(ASrAOGEN) were also greatly attenuated by 42% and
68%, respectively, when compared to those evoked in SD rats
(Fig. 5).
The results reported above included only animals for
which histological analysis showed injection sites located
within or immediately on the borders of the PVN, from of 1.4
to 2.1 caudal to the bregma according to the atlas of Paxinos
& Watson (Paxinos and Watson, 1986). Examples of the
injection sites included in the analysis are illustrated in Fig. 6.3. Discussion
The results of the present study confirm and extend previous
findings indicating that the brain levels of Ang II and
Ang-(1–7) aremarkedly reduced in the brain of TGR(ASrAOGEN)
while plasma levels are unchanged (Caligiorne et al., 2008;
Huang et al., 2001). We also found that the cardiovascular and
sympathetic responses evoked by interference with GABAA
receptors in the PVN are attenuated in TGR(ASrAOGEN). The
current experiments provide further support for the hypothesis
of an excitatory role for angiotensin peptides in the hypotha-
lamic paraventricular nucleus in the regulation of sympathetic
outflow.
It was previously reported that TGR(ASrAOGEN) exhibits
more than a 90% reduction in AOGEN levels in the brain
while plasma levels are unchanged (Schinke et al., 1999).
This reduction is pronounced in the hypothalamus and
medulla (Schinke et al., 1999). These brain regions are known
as sites of action for Ang II and Ang-(1–7) within specific
nuclei involved in the maintenance of sympathetic output
Fig. 1 – Brain and plasma profile of renin-angiotensin system components measured via radioimmunoassay. SD, Sprague
Dawley rats; TGR, TGR(ASrAOGEN) (see text for details). *P<0.05 compared with control SD rats (Student's t test).
Table 1 – Basal values for MAP and HR before muscimol
microinjections into the PVN.
Experimental group n MAP (mm Hg) HR (bpm)
SD Mus (1 nmol/100 nL) 5 101±3 299±3
TGR Mus (1 nmol/100 nL) 6 89±4 290±20
SD Bic (1 nmol/100 nL) 4 96±2 356±17
TGR Bic (1 nmol/100 nL) 4 94±3 323±13
All values are expressed as mean±SEM. Data analyzed by ANOVA
followed by Newman Keuls. MAP, mean arterial pressure; HR,
Heart Rate.
103B R A I N R E S E A R C H 1 4 4 8 ( 2 0 1 2 ) 1 0 1 – 1 1 0and blood pressure, including the PVN and rostral ventrolateral
medulla (RVLM) (Chen and Toney, 2003; Dampney et al., 2002a,
2002b; Fontes et al., 1994; Silva et al., 2005). While brain Ang II
and Ang-(1–7) are reduced in the TGR(ASrAOGEN), we observed
that plasma levels of Ang II, Ang-(1–7), Ang I and renin were
unaltered in TGR(ASrAOGEN). The data are consistent with the
hypothesis that the different functional findings observed in
this model are due, at least in part, to a reduction in the activity
of brain Ang II and Ang-(1–7).
Strikingly, we found that injection of muscimol into the
PVN of TGR(ASrAOGEN) resulted in an attenuated fall in
blood pressure, heart rate and RSNA when compared to the
effect observed in SD rats. It is of interest to mention that
muscimol is a powerful neuronal inhibitor acting as an
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Fig. 2 – Grouped data showing changes in mean arterial
pressure (A; MAP, mm Hg), heart rate (B; HR, bpm) and
(C) renal sympathetic nerve activity (C; RSNA, % of baseline)
evoked by unilateral (at 0 min) and contralateral (at 15 min)
nanoinjections of muscimol (1 nmol/100 nL) into the PVN of
TGR(ASrAOGEN) (TGR) or SD rats. * P<0.05 compared to SD
group (Two-way ANOVA).
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possess (Brown et al., 1981). Microinjections of muscimol into
the PVN decreases blood pressure, heart rate and sympathetic
activity, as observed in the control experiments in this and
other previous studies (Allen, 2002; Ito et al., 2002; Silva et al.,
2005). This attenuated effect leads us to conclude that the sym-
pathetic output generated by PVN neurons in TGR(ASrAOGEN)
is suppressed. In addition, the fall in MAP, HR and RSNA
produced by intravenous hexamethonium was significantly
reduced inTGR(ASrAOGEN) suggesting that overall sympathetic
activity is reduced in this transgenic rat lineage. Our current
results are in agreement with previous findings showing that
the stress induced increases in blood pressure and plasma
renin activity is greatly attenuated in this TGR model (Baltatu
et al., 2004b). Since these effects are mediated by sympathetic
reactivity, it further supports our conclusions.
Therefore, together with our current data showing a large
reduction in brain levels of Ang II and Ang-(1–7) in thistransgenic rat model, it is reasonable to suggest that the
suppressed sympathetic outflow mediated by PVN neurons
in TGR(ASrAOGEN) might be a consequence of the reduced
excitatory activity exerted by angiotensin peptides in this
premotor neuronal group. In this regard, the participation of
RAS peptides in the PVN maintaining sympathetic outflow
and blood pressure has been extensively investigated. All
components of the RAS exist in the PVN (Ferguson and
Washburn, 1998). Ang II and Ang-(1–7) can influence the
excitability of PVN neurons (Ambuhl et al., 1992, 1994; Cato and
Toney, 2005; Felix et al., 1991; Zhang et al., 2002b) and modulate
sympathetic activity (Silva et al., 2005; Tagawa and Dampney,
1999). Taking into account that thedeficiencyofAOGENsynthesis
is particularly evident in the hypothalamus of TGR(ASrAOGEN)
(Schinke et al., 1999), it is likely that the formation of Ang II or
Ang-(1–7) is also diminished in the PVN of this rat lineage.
Assuming this possibility, the angiotensinergic excitatory drive
over PVN neurons (Ambuhl et al., 1992; Cato and Toney, 2005;
Zhang et al., 2002b) would also be reduced. At least for Ang II, a
previous report showing that the AT1 receptor binding is signifi-
cantly higher in the PVN of TGR(ASrAOGEN) corroborates this
hypothesis (Monti et al., 2001).
This hypothesis is also supported by additional experiments
where we found that the increases in HR and RSNA evoked by
removal of gabaergic tone produced by injection of bicuculline
into the PVN of TGR(ASrAOGEN) was largely suppressed when
compared to that observed in control rats. The increased neuro-
nal activity through disinhibition must include a mechanism
responsible for exciting a specific neuronal population. In the
case of PVN, itwaspreviously demonstrated inSprague–Dawley
rats that pressor, tachycardic and renal sympathoexcitatory
responses to bicuculline injection into this nucleus were signif-
icantly attenuated by prior blockade of local AT1 receptors
(Chen and Toney, 2003). This finding provided evidence that at
least part of the source of excitation that contributes to the
autonomic responses produced by GABAA receptor blockade in
the PVN depend on activation of local AT1 receptors (Chen and
Toney, 2003). Therefore, it is reasonable to conclude that the
suppressed cardiac and renal sympathoexcitatory responses
observed after injection of bicuculline into the PVN of
TGR(ASrAOGEN) is due to a reduction in the excitatory input
mediated by endogenous Ang II, and possibly Ang-(1–7) into
this nucleus.
It could be argued that part of the response attributed to
muscimol in this study is a consequence of the diffusion of
this agent to the dorsomedial hypothalamus (DMH). Since
the spreading of muscimol into the hypothalamus was not
strictly defined, we cannot discard such possibility. However,
as shown in the histological analysis our injectionswere all tar-
geted to the PVN, which anatomical landmarks are easily iden-
tifiable. Second, the role of PVN in the maintenance of blood
pressure and sympathetic activity is well known (Coote, 2005),
as well as the effects of muscimol in the PVN, including using
similar volume and dose (Allen, 2002; Silva et al., 2005; Zhang et
al., 2002a). In spite of this, the cardiovascular reactivity to stress
in TGR(ASrAOGEN) is largely suppressed when compared to SD
rats (Baltatu et al., 2004a). Since the DMH is a key nucleus for
the cardiovascular response to emotional stress (DiMicco et al.,
2002) it is quite possible that the reactivity of DMH neurons in
this transgenic rat can also be altered as a result of reduced
Fig. 3 – Panels A and B— Original recordings of renal sympathetic nerve activity (RSNA, V) illustrating the baseline period and
changes induced by nanoinjections of muscimol 15 min after the bilateral injection (1 nmol/100 nL) into the PVN of SD (panel A)
or TGR(ASrAOGEN) (TGR) (panel B). Panel C— Baseline and mean maximum renal sympathetic nerve activity changes (RSNA,
spikes/s) measured after injections of muscimol (1 nmol/100 nL) into the PVN of SD rats or TGR. The significance between
groups is shown in panel D after taking the difference of the two repeated measures (before and after as shown in Fig. 3C) for
each group.* P<0.05 for TGR vs SD (unpaired t test).
105B R A I N R E S E A R C H 1 4 4 8 ( 2 0 1 2 ) 1 0 1 – 1 1 0angiotensin peptides in the brain. However, other experiments
are necessary to further confirm this hypothesis.
It is important to mention that, apart from hypothalamus,
there are other brain regions where the reduction in the
excitatory drive exerted by angiotensins could influence in
the sympathetic activity and cardiovascular function. In this
regard we have previously reported that microinjections of
Ang II into the RVLM of TGR(ASrAOGEN) evoked a larger
pressor effect when compared to control rats (Baltatu et al.,
2001). As mentioned above, the reduction of AOGEN is
pronounced in the medulla of TGR(ASrAOGEN) (Schinke et
al., 1999). Altogether, these findings suggests that a reduction
of angiotensinogen in the medulla of this rat lineage leads to
an increased sensitivity of Ang II receptors in the RVLM due
to the absence of endogenous formation of Ang II. Therefore,
because the RVLM is a key brain region involved in the mainte-
nance of sympathetic activity and blood pressure, it is possible
that the reduction of the excitatory input exerted by Ang II
in the RVLM (Dampney et al., 2002b) may additionally con-
tribute to the reduced sympathetic outflow observed in
TGR(ASrAOGEN).
The question then arises as to why the basal RSNA is
similar in TGR(ASrAOGEN) and SD if the sympathetic outflow
mediated by PVN neurons in TGR(ASrAOGEN) is largely
suppressed. Based on current data we cannot account for the
underlying mechanisms responsible for this paradox. The
simplest explanation is that, as a result of reduced excitatory
drive exerted by angiotensins in the PVN of TGR(ASrAOGEN),
another sympathetic premotor group could maintain the
sympathetic outflow to the kidney stabilizing the RSNA base-
line levels. This hypothesis is plausible since other neuronalcircuits responsible for maintaining normal levels of blood
pressure and sympathetic tone in anesthetized conditions
are particularly located caudal to midbrain (Koshiya and
Guyenet, 1994).
In conclusion, the results of our study indicate that the
contribution of PVN to the renal sympathetic outflow is
reduced in rats with low synthesis of brain AOGEN. It is possi-
ble that, this reduction is due to a diminished excitatory drive
resulting from lowered hypothalamic angiotensins produc-
tion in this rat lineage. Finally, our findings reinforce the
need for further investigation of the contribution of Ang pep-
tides in the PVN during pathophysiological conditions, such
as hypertension or chronic heart failure.4. Experimental procedures
4.1. General procedures
Adult male TGR(ASrAOGEN) and Sprague–Dawley (SD) Hanover
rats,weighing 400–450 g,wereobtained fromtheanimal breeding
unit of the Hypertension Laboratory at the Biological Sciences
Institute (UFMG, Belo Horizonte, MG, Brazil). All experiments
conform to the regulation set forth by National Institutes of
Health (NIH) Guidelines for the Care and Use of Laboratory
Animals (NIH publication 80–23, revised in 1996) and were also
approved by our local Institutional Animal Welfare Committee
(CETEA–UFMG, protocol number: 137/2006). Under urethane
anesthesia (1.2 to 1.4 g/kg i.p.), catheters were placed in a femoral
artery and vein, followed by tracheotomy. The adequate quantity
of anesthesia was verified by the absence of a withdrawal
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Fig. 4 – Cardiovascular effects produced by intravenous injection of the autonomic ganglion blocking agent hexamethonium
(2.5 mg/kg, Sigma) in TGR(ASrAOGEN) and SD rats (n=5 per group). (A) Time course and (B)maximumchanges in cardiovascular
variables during the period recorded. * P<0.05 compared to SD group (unpaired t test).
106 B R A I N R E S E A R C H 1 4 4 8 ( 2 0 1 2 ) 1 0 1 – 1 1 0response to nociceptive stimulation of the hindpaw. Supplemen-
tal doses of urethane (0.1 g/kg i.v.) were administered when
necessary. Temperature was monitored and maintained in the
range of 36.5 °C to 37.5 °C with a heating lamp. The head was
placed in a stereotaxic frame with the tooth bar fixed −3.3 mm
below the interaural line. A small craniotomy was made near
the bregma to allow for a later insertion of a micropipette into
the PVN.
4.2. Renal SNA recording
Renal nerve recording was performed as previously described
(Silva et al., 2005). Briefly, the left kidney was exposed using a
retroperitoneal approach. A nerve fascicle to the kidney was
isolated, placed on a bipolar recording electrode and covered
with mineral oil. The neural signals were amplified by 10 K,
passed through a band pass filter (100–1000 Hz, Tektronix),
displayed on a cathode ray oscilloscope (Tektronix) and
monitored by means of an audio amplifier. The filtered
nerve activity signal was rectified, integrated (resetting every
2 s) and collected for displaying and later analysis using a
Power Lab data acquisition system (AD Instruments). All
data were digitized at 1 kHz and stored in a PC.4.3. Experimental protocol
For the duration of each experiment, MAP, HR and RSNA were
recorded continuously (Power Lab, ADInstruments). After all
surgical procedureswere completed there was a waiting period
of 20 min, to allow the measured cardiovascular variables to
stabilize. The baseline MAP, HR and RSNA were then recorded
for a 20 min period that was followed by microinjection
procedures.
4.4. Activation and blockade of GABAA receptors in the PVN,
intravenous injection of hexamethonium
Activation and blockade of GABAA receptors was performed
by microinjecting the GABAA agonist muscimol (1 nmol/
100 nL, Sigma) or the antagonist bicuculline methiodide
(20 pmol/100 nL, Sigma), respectively, bilaterally into the
PVN. Each compound was tested in separated group of rats.
The effects were compared between TGR(ASrAOGEN) and SD
rats (n=5–6 per group). A 30-gauge injection needle connected
to a Hamilton syringe (5 μL) was used as described previously
(Silva et al., 2005). The coordinates for microinjections were
determined by the atlas of Paxinos and Watson (Paxinos and
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Fig. 5 – Average grouped results for the increases in mean
arterial pressure (MAP) (panel A), heart rate (HR) (panel B) or
renal sympathetic nerve activity (RSNA) (panel C) evoked by
bilateral nanoinjection of bicuculline (BMI, 20 pmol/100 nL)
into the PVN of TGR(ASrAOGEN) (TGR) (black bars) or SD rats
(white bars). *P<0.05 compared with the effect produced by
microinjection of BMI into the PVN of SD rats (unpaired
t test).
107B R A I N R E S E A R C H 1 4 4 8 ( 2 0 1 2 ) 1 0 1 – 1 1 0Watson, 1986) in the track located 1.8 mm posterior, 0.5 mm
lateral to the bregma and at a depth of 7.8 mm below the
dura. At the end of each experiment, a bilateral microinjection
of 2% alcian blue dye (100 nL) was made, locating the sites of
injection within the PVN, which was confirmed histologically,
as described previously (da Silva et al., 2011). In additional
groups of experiments, the cardiovascular effects produced
by intravenous injection of the autonomic ganglion blocking
agent hexamethonium (2.5 mg/kg, Sigma) was compared
between TGR(ASrAOGEN) and SD rats (n=5 per group).
4.5. Peptides measurement
Animals were killed by decapitation and the trunk blood was
rapidly collected into chilled tubes containing EDTA (for plasma
renin activity) or 1 mM p-hydroxymercuribenzoate, 30mM of
1,10-phenanthroline, 1 mM phenylmethylsulphonyl fluoride
(PMSF), 1 mM pepstatin A, and 7.5% EDTA (140 μL/mL of blood)
for angiotensin measurements. In parallel, whole brain was
quickly removed and frozen in liquid nitrogen and stored at
−80 °C until assayed. After centrifugation, plasma samples
were frozen in dry ice and stored at −20 °C. The brain washomogenized in 3 mL of HCl 0.045 N in ethanol containing
0.90 μM p-hydroxymercuribenzoate, 131.50 μM 1,10-o-phenan-
throline, 0.90 μM PMSF, 1.75 μM pepstatin A, 0.032% EDTA and
5 μL of 5% protease-free bovine serum albumin (BSA). Next,
plasma and brain homogenates were extracted using C18
Bond Elut cartridges (Analytichem International, Harbor City,
CA) aspreviouslydescribed (Botelho et al., 1994).After extraction,
samples were evaporated and resuspended in 500 μL of aqueous
solution containing 0.1% BSA, 0.9% NaCl and 0.03% acetic acid.
Angiotensin concentration was corrected for total protein
determined by the Bradford method (Bradford, 1976).
4.6. Data analysis
To compare baseline RSNA between TGR(ASrAOGEN) and SD
rats, the number of spikes of identified action potentials in
the raw and filtered recordings was averaged using the Lab
Chart/Spike histogram tool from (LabChart Pro 7.2 software —
ADInstruments, Australia). For that, the background noise was
determined from the post-mortem noise at the end of each ex-
periment as previously reported for similar analysis (Hamza
and Kaufman, 2007; Iwashita et al., 2002). A 5 min period of
the background noise recording was selected, a 10 s bin was
reselected by zooming (polarity turned positive), and the
threshold was determined (mean maximum amplitude value
averaged from noise level). Following, a 5 min period of the
experimental recording was selected, a 10 s bin was rese-
lected and the detected threshold was informed to the soft-
ware. Starting from the threshold, the rate of spikes was
determined as spikes/second (see details in methodological
supplement). The RSNA responses evoked by injections into
the PVN were also expressed as percent changes from
baseline, calculated by the integrated voltage. The integrated
voltage obtained during background noise was subtracted
from the integrated voltage recorded during baseline and
experimental recording periods.
The baseline values of MAP and HR were measured as the
average values of these variables for the 1-minute period
immediately preceding microinjections procedures. Experi-
mental values were obtained from a mean across 1-minute,
collected in 5 min intervals for the duration of the experiment.
Statistical comparisons between the baseline values of
MAP and HR were assessed by ANOVA followed by Newman
Keuls. Changes from baseline evoked by injection of drugs
were assessed by paired t-test. Comparisons between
responses evoked by injections of drugs into PVN of SD and
TGR(ASrAOGEN) groups were determined by two-way
ANOVA followed by Bonferroni post-hoc test or Student's
t-test. Differences in peptide concentrations between SD and
TGR(ASrAOGEN) were assessed by unpaired t-test. A value of
P<0.05 was taken to indicate a statistically significant differ-
ence. All values are presented as mean±SEM.Acknowledgments
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